The C/EBPδ Protein is Stabilized by Estrogen Receptor α Activity, Inhibits SNAI2 Expression and Associates with Good Prognosis in Breast Cancer
Overview
Authors
Affiliations
Hypoxia and inflammatory cytokines like interleukin-6 (IL-6, IL6) are strongly linked to cancer progression, and signal in part through the transcription factor Ccaat/enhancer-binding protein δ (C/EBPδ, CEBPD), which has been shown to promote mesenchymal features and malignant progression of glioblastoma. Here we report a different role for C/EBPδ in breast cancer. We found that the C/EBPδ protein is expressed in normal breast epithelial cells and in low-grade cancers. C/EBPδ protein (but not mRNA) expression correlates with estrogen receptor (ER+) and progesterone receptor (PGR) expression and longer progression-free survival of breast cancer patients. Specifically in ER+ breast cancers, CEBPD-but not the related CEBPB-mRNA in combination with IL6 correlated with lower risk of progression. Functional studies in cell lines showed that ERα promotes C/EBPδ expression at the level of protein stability by inhibition of the FBXW7 pathway. Furthermore, we found that C/EBPδ attenuates cell growth, motility and invasiveness by inhibiting expression of the SNAI2 (Slug) transcriptional repressor, which leads to expression of the cyclin-dependent kinase inhibitor CDKN1A (p21). These findings identify a molecular mechanism by which ERα signaling reduces the aggressiveness of cancer cells, and demonstrate that C/EBPδ can have different functions in different types of cancer. Furthermore, our results support a potentially beneficial role for the IL-6 pathway specifically in ER+ breast cancer and call for further evaluation of the role of intra-tumoral IL-6 expression and of which cancers might benefit from current attempts to target the IL-6 pathway as a therapeutic strategy.
Hartl L, Duitman J, Aberson H, Medema J, Bijlsma M, Spek C J Cell Mol Med. 2025; 29(3):e70287.
PMID: 39887610 PMC: 11783153. DOI: 10.1111/jcmm.70287.
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.
Panda V, Mishra B, Mahapatra S, Swain B, Malhotra D, Saha S Cancers (Basel). 2025; 17(2).
PMID: 39858015 PMC: 11763662. DOI: 10.3390/cancers17020234.
FBXW7 in breast cancer: mechanism of action and therapeutic potential.
Chen S, Leng P, Guo J, Zhou H J Exp Clin Cancer Res. 2023; 42(1):226.
PMID: 37658431 PMC: 10474666. DOI: 10.1186/s13046-023-02767-1.
Balamurugan K, Poria D, Sehareen S, Krishnamurthy S, Tang W, McKennett L JCI Insight. 2023; 8(6).
PMID: 36757813 PMC: 10070121. DOI: 10.1172/jci.insight.156057.
C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC.
Hartl L, Roelofs J, Dijk F, Bijlsma M, Duitman J, Spek C Int J Mol Sci. 2023; 24(2).
PMID: 36675048 PMC: 9867044. DOI: 10.3390/ijms24021537.